Stocks
Halozyme Financial Statements (HALO) |
||||||||||
| Halozymesmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 23.02.2021 | 22.02.2022 | 31.12.2022 | 21.02.2023 | 20.02.2024 | 31.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 267.6 | 443.3 | 660.1 | 660.1 | 829.3 | 947.4 | |||
| Operating Income, bln rub | 144.3 | 275.9 | 267.5 | 267.5 | 337.6 | 477.0 | ||||
| EBITDA, bln rub | ? | 153.0 | 259.0 | 315.5 | 315.5 | 451.9 | 570.5 | |||
| Net profit, bln rub | ? | 129.1 | 402.7 | 202.1 | 202.1 | 281.6 | 392.5 | |||
| OCF, bln rub | ? | 55.5 | 299.4 | 240.1 | 240.1 | 388.6 | 403.0 | |||
| CAPEX, bln rub | ? | 2.50 | 1.46 | 4.81 | 4.81 | 15.3 | 10.2 | |||
| FCF, bln rub | ? | 53.0 | 298.0 | 235.3 | 235.3 | 373.3 | 392.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 13.5 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.44% | ||||
| OPEX, bln rub | 80.0 | 86.0 | 253.3 | 253.3 | 299.3 | 247.4 | ||||
| Cost of production, bln rub | 43.4 | 81.4 | 139.3 | 139.3 | 192.4 | 205.2 | ||||
| R&D, bln rub | 34.2 | 35.7 | 66.6 | 66.6 | 76.4 | 79.9 | ||||
| Interest expenses, bln rub | 20.4 | 7.53 | 16.9 | 16.9 | 18.8 | 18.8 | ||||
| Assets, bln rub | 579.9 | 1 104 | 1 842 | 1 842 | 1 733 | 2 118 | ||||
| Net Assets, bln rub | ? | 151.0 | 197.0 | 169.8 | 169.8 | 83.8 | 452.7 | |||
| Debt, bln rub | 397.2 | 876.7 | 1 506 | 1 506 | 1 499 | 1 504 | ||||
| Cash, bln rub | 368.0 | 740.9 | 362.8 | 362.8 | 336.0 | 666.3 | ||||
| Net debt, bln rub | 29.2 | 135.8 | 1 143 | 1 143 | 1 163 | 837.8 | ||||
| Ordinary share price, rub | 42.7 | 40.2 | 56.9 | 56.9 | 37.0 | 34.3 | ||||
| Number of ordinary shares, mln | 136.2 | 140.6 | 136.8 | 136.8 | 131.9 | 126.9 | ||||
| Market cap, bln rub | 5 817 | 5 655 | 7 786 | 7 786 | 4 876 | 4 351 | ||||
| EV, bln rub | ? | 5 847 | 5 791 | 8 930 | 8 930 | 6 039 | 5 189 | |||
| Book value, bln rub | 151 | 197 | -786 | -786 | -806 | -384 | ||||
| EPS, rub | ? | 0.95 | 2.86 | 1.48 | 1.48 | 2.13 | 3.09 | |||
| FCF/share, rub | 0.39 | 2.12 | 1.72 | 1.72 | 2.83 | 3.10 | ||||
| BV/share, rub | 1.11 | 1.40 | -5.74 | -5.74 | -6.11 | -3.02 | ||||
| EBITDA margin, % | ? | 57.2% | 58.4% | 47.8% | 47.8% | 54.5% | 60.2% | |||
| Net margin, % | ? | 48.2% | 90.8% | 30.6% | 30.6% | 34.0% | 41.4% | |||
| FCF yield, % | ? | 0.91% | 5.27% | 3.02% | 3.02% | 7.66% | 9.03% | |||
| ROE, % | ? | 85.5% | 204.5% | 119.0% | 119.0% | 336.0% | 86.7% | |||
| ROA, % | ? | 22.3% | 36.5% | 11.0% | 11.0% | 16.2% | 18.5% | |||
| P/E | ? | 45.1 | 14.0 | 38.5 | 38.5 | 17.3 | 11.1 | |||
| P/FCF | 109.9 | 19.0 | 33.1 | 33.1 | 13.1 | 11.1 | ||||
| P/S | ? | 21.7 | 12.8 | 11.8 | 11.8 | 5.88 | 4.59 | |||
| P/BV | ? | 38.5 | 28.7 | -9.91 | -9.91 | -6.05 | -11.3 | |||
| EV/EBITDA | ? | 38.2 | 22.4 | 28.3 | 28.3 | 13.4 | 9.10 | |||
| Debt/EBITDA | 0.19 | 0.52 | 3.62 | 3.62 | 2.57 | 1.47 | ||||
| R&D/CAPEX, % | 1 367% | 2 448% | 1 385% | 1 385% | 499.3% | 780.7% | ||||
| CAPEX/Revenue, % | 0.94% | 0.33% | 0.73% | 0.73% | 1.84% | 1.08% | ||||
| Halozyme shareholders | ||||||||||
